Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer. Recently,
we started the first-in-human treatment with an α-radionuclide–labeled PSMA ligand. …

Background: Recent reports of the remarkable therapeutic efficacy of 225Ac-labeled PSMA-
617 for therapy of metastatic castration-resistant prostate cancer have underlined the clinical …

The feasibility of producing Ac-225 by proton irradiation of Ra-226 in a cyclotron through the
reaction Ra-226(p,2n)Ac-225 has been experimentally demonstrated for the first time. …

The alpha emitters 225Ac and 213Bi are promising therapeutic radionuclides for application
in targeted alpha therapy of cancer and infectious diseases. Both alpha emitters are …

The aim of this study was to develop a treatment protocol for 225 Ac-PSMA-617 α-radiation
therapy in advanced-stage, metastatic castration-resistant prostate cancer patients with …

Encouraging results from targeted α-therapy have received significant attention from academia
and industry. However, the limited availability of suitable radionuclides has hampered …

This study evaluates targeted liposomes loaded with the α-particle generator 225 Ac to
selectively kill prostate-specific membrane antigen (PSMA)–expressing cells with the aim to …

Human epidermal growth factor receptor type 2 (HER2) is overexpressed in numerous
carcinomas. Nanobodies (Nbs) are the smallest antibody-derived fragments with beneficial …

Purpose Radiopeptide therapy using a somatostatin analogue labelled with a beta emitter
such as 90 Y/ 177 Lu-DOTATOC is a new therapeutic option in neuroendocrine cancer. …

The aim of this evaluation was to identify the first indicators of efficacy for 225 Ac-labeled
prostate-specific membrane antigen (PSMA)–617 therapy in a retrospectively analyzed group …